FindTrial
Sign In

A Study on the use of imeglimin

Prospective Cohort Study on Imeglimin: Safety, Efficacy, and Acceptability in Type 2 Diabetes Management - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/082295
Enrollment
70
Registered
2025-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: NA: NA

Sponsors

Sri ramachandra Institute of higher education and research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who are 18 years of age and older. 2. Patients only with type 2 diabetes mellitus . 3. Patients who are receiving Imeglimin. 4. Patients receiving Imeglimin for atleast 3 months.

Exclusion criteria

Exclusion criteria: 1. Patient who are intolerant to imeglimin. 2. Patient who have stopped taking imeglimin . 3. Patient unwilling to give written informed consent.

Design outcomes

Primary

MeasureTime frame
The Study Safety, Efficacy and Patient Acceptability outcomes will focus on identifying adverse drug reactions (ADRs) associated with imeglimin, including their frequency and severity.Timepoint: 1 Month—

Secondary

MeasureTime frame
The study will likely support oral Imeglimin as an effective and safe treatment option, contributing to better management of diabetes for the population. Timepoint: 1 Month—

Countries

India

Contacts

Public ContactDr. Adlyne Reena Solomon

SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH.

amb@sriramachandra.edu.in9488588735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026